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Abstract. 
 
The orphan nuclear estrogen receptor–
 
related receptor 
 
  
 
(ERR
 
 
 
), is expressed by many cell
types, but is very highly expressed by osteoblastic cells
in which it transactivates at least one osteoblast-associ-
ated gene, osteopontin. To study the putative involve-
ment of ERR
 
 
 
 in bone, we ﬁrst assessed its expression
 
in rat calvaria (RC)
 
 
 
in vivo
 
 
 
and in RC cells
 
 
 
in vitro.
ERR
 
 
 
 mRNA and protein were expressed at all devel-
opmental stages from early osteoprogenitors to bone-
forming osteoblasts, but protein was most abundant in
mature cuboidal osteoblasts. To assess a functional role
for ERR
 
 
 
 in osteoblast differentiation and bone forma-
tion, we blocked its expression by antisense oligonucle-
otides in either proliferating or differentiating RC cell
cultures and found inhibition of cell growth and a pro-
liferation-independent inhibition of differentiation. On
the other hand, ERR
 
 
 
 overexpression in RC cells in-
creased differentiation and maturation of progenitors
to mature bone-forming cells. Our ﬁndings show that
ERR
 
 
 
 is highly expressed throughout the osteoblast
developmental sequence and plays a physiological role
in differentiation and bone formation at both prolifera-
tion and differentiation stages. In addition, we found
that manipulation of receptor levels in the absence of
known ligand is a fruitful approach for functional anal-
ysis of this orphan receptor and identiﬁcation of poten-
tial target genes.
Key words: osteoblasts • bone • nuclear receptor • es-
trogen related • differentiation
 
Introduction
 
Nuclear receptors are transcription factors involved in var-
ious physiological regulatory processes. The superfamily
to which nuclear receptors belong comprises both ligand-
dependent molecules such as the steroid hormone-, thy-
roid hormone-, retinoic acid-, and vitamin D receptors,
and an increasing number of so-called orphan receptors
for which no ligand has yet been determined (Gronemeyer
and Laudet, 1995; Enmark and Gustafsson, 1996). The or-
phan receptors display the same structural organization as
do the classic ligand-dependent receptors: the A/B domain
located in the NH
 
2
 
-terminal part of the protein harbors a
ligand-independent transactivation function (AF-1); the C
domain, which is the most conserved part of the molecule,
is responsible for the specific DNA-binding activity; the E
domain contains the ligand binding hydrophobic pocket
and contributes to receptor dimerization and to the ligand-
dependent transactivation function (AF-2).
Two orphan receptors, estrogen receptor–related recep-
tor 
 
 
 
 (ERR
 
 
 
)
 
1
 
 and ERR
 
 
 
 ([Giguere et al., 1988]; NR3B1
and NR3B2, respectively, according to the Nuclear Recep-
tors Nomenclature Committee, 1999 [Committee, 1999])
are closely related to the estrogen receptors ER
 
 
 
 and
ER
 
 
 
 ([Green et al., 1986; Kuiper et al., 1996]; NR3A1 and
NR3A2, respectively). ERR
 
 
 
 was identified by low-strin-
gency screening of cDNA libraries with a probe encom-
passing the DNA-binding domain of the human estrogen
receptor (ER). Recently, a third ERR, ERR3 or ERR
 
 
 
,
was identified by yeast two-hybrid screening with the glu-
cocorticoid receptor–interacting protein 1 (GRIP1) as bait
(Hong et al., 1999). The DNA binding domain of ERRs
and ERs is highly conserved; however, the other parts of
the protein share very little homology (Giguere et al.,
1988; Hong et al., 1999). Therefore, sequence alignment of
ERR
 
 
 
 and the ERs reveals a high similarity (68%) in the
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66 amino acids of the DNA-binding domain and a moder-
ate similarity (36%) in the ligand-binding E domain, which
may explain the fact that ERR
 
 
 
 does not bind estrogen.
Although ligands for the ERRs have not been clearly
identified, the pesticides chlordane and toxaphene have
been suggested to be potential ligands for ERR
 
 
 
 (Yang
and Chen, 1999). ERR
 
 
 
 has been identified as a regulator
of fat metabolism (Sladek et al., 1997; Vega and Kelly,
1997), as a regulator of the human aromatase gene in
breast, a modulator of estrogen activity on the lactoferrin
promoter (Yang et al., 1996; Zhang and Teng, 2000), and it
has been hypothesized to be critical for normal breast de-
velopment (Yang et al., 1998).
Postmenopausal osteoporosis is a condition caused pri-
marily by the severe decrease of serum estrogen levels af-
ter cessation of ovarian function (Turner et al., 1994). ERs
are expressed in osteoblasts (Eriksen et al., 1988; Komm et
al., 1988; Turner et al., 1994) but mice lacking a functional
ER
 
 
 
 or ER
 
 
 
 have relatively minor skeletal abnormalities
(Korach, 1994; Windahl et al., 1999) suggesting that other
mechanisms or receptors might be important during skele-
tal development. Due to their homology to the ERs, we
hypothesized that ERR
 
 
 
 may intervene in the signals in-
duced by estrogen in bone. ERR
 
 
 
 has a broad spectrum of
expression, including fat, muscle, brain, testis, and skin
(Bonnelye et al., 1997b). Strikingly, ERR
 
 
 
 is also highly
expressed in the ossification zones of the mouse embryo
(in long bones, vertebrae, ribs, and skull), and is more
widely distributed in osteoblast-like cells than is ER
 
 
 
(Bonnelye et al., 1997a). Moreover it has been shown that
ERR
 
 
 
 positively regulates the osteopontin (OPN) gene
(Vanacker et al., 1998b), an extracellular matrix molecule
secreted by osteoblasts and thought to play a role in bone
remodeling (Denhardt and Noda, 1998).
Given these observations, we sought to assess more di-
rectly whether ERR
 
 
 
 plays a functional role in osteoblast
development and bone formation. Our findings show that
ERR
 
 
 
 is highly expressed and widely distributed in differ-
entiating osteoblastic cells. They also indicate a critical
role for ERR
 
 
 
 in bone formation, with both up- and
downregulation of bone nodule formation concomitant
with up- and downregulation of ERR
 
 
 
 expression in vitro.
These data suggest that ERR
 
 
 
 plays a widespread and
physiologically relevant role in bone formation and pre-
dict specific ERR
 
 
 
 target genes at different osteoblast de-
velopmental time windows.
 
Materials and Methods
 
Cell Culture
 
Cells were enzymatically isolated from the calvaria of 21-d Wistar rat fe-
tuses by sequential digestion with collagenase as described previously
(Bellows et al., 1986). Cells obtained from the last four of the five diges-
tion steps (populations II–V) were plated in T-75 flasks in 
 
 
 
-MEM con-
taining 15% heat-inactivated FBS (Flow Laboratories) and antibiotics
comprising 100 
 
 
 
g/ml penicillin G (Sigma-Aldrich), 50 
 
 
 
g/ml gentamycin
(Sigma-Aldrich), and 0.3 
 
 
 
g/ml fungizone (Flow Laboratories). After 24 h
incubation, attached cells were washed with PBS to remove nonviable
cells and other debris, and then collected by trypsinization using 0.01%
trypsin in citrate saline. Aliquots were counted with a Coulter Counter
(Coulter Electronics), and the remaining cells were resuspended in the
standard medium described above. The resuspended cells were plated
into 100-mm tissue culture dishes at 10
 
5 
 
cells/dish, into 35-mm tissue cul-
 
ture dishes at 2 
 
  
 
10
 
4
 
/dish, and in 24-well plates at 10
 
4
 
 cells/well. After
24 h incubation, medium was changed and supplemented with 50 
 
 
 
g/ml
ascorbic acid, 10 mM sodium 
 
 
 
-glycerophosphate, and with or without
10
 
 
 
8
 
 M dexamethasone (Merck, Sharp, and Dohme, Canada, Ltd.). Me-
dium was changed every 2 d. All dishes were incubated at 37
 
 
 
C in a hu-
midified atmosphere in a 95% air/5% CO
 
2
 
 incubator.
 
Northern Blots
 
Total RNA was extracted with guanidine from rat calvaria (RC) cells at
different times of the culture corresponding to different stages of prolifer-
ation, differentiation, and bone nodule formation (Ausubel et al., 1996).
Northern blots were prepared and hybridized with a 750-bp fragment cor-
responding to the rat 3
 
 
 
 untranslated region (UTR) of ERR
 
 
 
 (provided
by J.M. Vanacker, CNRS, UMR 5665, Lyon, France) according to stan-
dard procedures (Chirgwin et al., 1979). Rat bone/liver/kidney alkaline
phosphatase (ALP; Noda et al., 1987; gift of Dr. G.A. Rodan, Merck Re-
search Laboratories, West Point, PA) was a 600-bp cDNA EcoRI frag-
ment obtained by digesting pRAP54 with BssHII-XhoI to remove 1.8 kb
of the 5
 
 
 
 region and relegating the blunt ends. Rat OPN (provided by Dr.
R. Mukherjee, McGill University, Montreal, Quebec, Canada) was a 700-
bp cDNA BamHI-EcoRI fragment obtained by digesting the full-length
cDNA with PvuI to remove 800 bp of 5
 
 
 
 region and ligating the blunt
ended fragment into SmaI cut pGEM-7Zf(
 
 
 
) vector (Promega). Rat os-
teocalcin (OCN) was a partial cDNA containing 350 bp of the 3
 
 
 
UTR iso-
lated with OCN-specific primers from a 
 
 
 
gt11 library prepared from ROS
17/2.8 cells and rat L32 was generated from RC cell mRNA by PCR using
specifics primers (Liu et al., 1994).
 
Reverse Transcription PCR
 
Samples of total cellular RNA (1.5–5
 
 
 
g) were reverse transcribed using
oligo(dT) and the first strand synthesis kit of Superscript™ II (GIBCO
BRL). PCR was performed with specific primers specific for ERR
 
 
 
. Prim-
ers were as follows: ERR
 
 
 
 upstream (3
 
 
 
UTR), CAG GAA AGT GAA
TGC CCA GG; ERR
 
 
 
 downstream (3
 
 
 
UTR), CTT TGC AGC AAA
TAT ACA TT; L32 upstream, CAT GGC TGC CCT TCG GCC TC; and
L32 downstream, CAT TCT CTT CGC TGC GTA GCC.
The PCR reaction mixture contained cDNA (1 
 
 
 
l), 1 
 
 
 
l dNTP mix (10
mM), 10
 
 
 
 PCR buffer, Q solution, 25 pmol primers, and 5 U of Taq poly-
merase from Quiagen. PCR was done for 25 cycles (94
 
 
 
C for 1 min, 55
 
 
 
C
for 1 min, 72
 
 
 
C for 1 min, and a final elongation step of 7 min at 72
 
 
 
C) for
ERR
 
 
 
 and L32. Amplimers were sequenced for verification.
Osteoblast associated and other markers were also amplified by PCR
using specific primers for rat OCN, OPN, ALP, bone sialoprotein (BSP),
Cbfa1, collagen type I 
 
 
 
 chain (COLLI), C-fos, cyclin D1, Bax, and Bcl-2.
PCR was done for 25 cycles (94
 
 
 
C for 1 min, 55
 
 
 
C for 1 min, 72
 
 
 
C for 1
min, and a final elongation step of 7 min at 72
 
 
 
C) for OCN, OPN, ALP,
BSP, L32, Bax, and 30 cycles for Bcl-2, 32 cycles for c-Fos, 35 cycles for cy-
clin D1 and Cbfa1 (with annealing temperatures of 58
 
 
 
C and 62
 
 
 
C, respec-
tively), and 23 cycles for COLLI with annealing temperature of 59
 
 
 
C.
Primers were OCN upstream: AGG ACC CTC TCT CTG CTC AC;
OC downstream: AAC GGT GGT GCC ATA GAT GC; BSP upstream:
CGC CTA CTT TTA TCC TCC TCT G; BSP downstream: CTG ACC
CTC GTA GCC TTC ATA G; ALP upstream: CCC GCA TCC TTA
AGG GCC AG; ALP downstream: TAG GCG ATG TCC TTG CAG C;
OPN upstream: GCC ACT TGG CTG AAG CCT G; OPN downstream:
GAA ACT CCT GGA CTT TGA CC; Cbfa1 upstream: CTT CAT TCG
CCT CAC AAA C; Cbfa1 downstream: CAC GTC GCT CAT CTT GCC
GG; cyclin D1 upstream: TCC CGC CAG CAG CAA GAC AC; cyclin
D1 downstream: TGA GCT TGT TCA CCA GAA GC; c-Fos upstream:
ATA GAG CCG GCG GAG CCG CG; c-Fos downstream: AAG CCC
CGG TCG ACG GGG TG; Bax upstream: CCT TGG AGC AGC CGC
CCC AG; Bax downstream: ATG TGG GCG TCC CGA AGT AGG;
Bcl-2 upstream: GGG GAA ACA CCA GAA TCA AG; Bcl-2 down-
stream: AGA GAA GTC ATC CCC AGC CC; COLLI upstream: GGA
GAG AGT GCC AAC TCC AG; COLLI downstream: CCA CCC CAG
GGA TAA AAA CT.
 
Poly(A) PCR Library Selection
 
19 poly(A) PCR libraries representative of five transitional stages in os-
teoblast lineage progression were selected from 
 
 
 
100 available amplified
colonies (Liu et al., 1994; Candeliere et al., 1999; Aubin and Liu, 1996). 
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Stage A are replica-plated monolayer colonies committed to differentiate
to the osteoblast lineage but not yet expressing type I 
 
 
 
I collagen or ALP,
both early markers of osteoprogenitor cells. Stage B and C colonies are
progressively more mature, i.e., expressing type I 
 
 
 
I collagen or both type
I 
 
 
 
I collagen and ALP, respectively. Stage D colonies represent multilay-
ered cells and contain histologically identifiable cuboidal osteoblasts.
Stage E colonies comprised terminal differentiation stages, with multilay-
ered cells and mineralized bone matrix.
Total RNA was extracted using a mini-guanidine thiocyanate method
as described previously (Liu et al., 1994). Globally amplified cDNA was
synthesized by oligo(dT) priming, poly(A) tailed, and amplified by PCR
with oligo(dT) primer (Liu et al., 1994). Total cDNA probe used as
“housekeeping control” was prepared as described by Sambrook et al.
(1989) from poly(A)
 
 
 
 mRNA isolated (Auffray and Rougeon, 1980) from
mass populations of fetal RC cells grown in the presence of dexametha-
sone in which bone nodules were beginning to mineralize. Amplified
cDNA (5 
 
 
 
l) was run on 1.5% agarose gels, transferred onto 0.2-
 
 
 
m pore
size nylon membrane (ICN Biomedicals), and immobilized by baking at
80
 
 
 
C for 2 h. Prehybridization and hybridization were performed as de-
scribed in Liu et al. (1994). After hybridization, the blots were washed at
65
 
 
 
C for 1 h each in 2
 
 
 
 SSC/0.1% SDS and in 0.5
 
 
 
 SSC/0.1% SDS. The
blots were then exposed to phosphorimager screens (Molecular Dynam-
ics), and digitized images obtained and quantified with the IPLab Gel pro-
gram (Signal Analytics Corp.). After quantifying the data, the signal in-
tensity for ERR
 
 
 
 was standardized against total cDNA.
 
Western Blots
 
Total protein was extracted from confluent HeLa and RC cells according
to standard methods (Ausubel et al., 1996). Western blot analyses were
performed using a semidry system. Immunoblotting was performed with
purified rabbit polyclonal antibody prepared against a mouse peptide
(NH-KAEPASPDSPKGSSETETE-C) localized in the A/B domain (14–
32 amino acids); blots were incubated overnight at room temperature with
the polyclonal antibody diluted to 1/60, and binding was detected using
HRPO-conjugated goat anti–rabbit antibodies (1/3,000; Bio-Rad Labora-
tories) and chemiluminescence.
 
Immunocytochemistry
 
Immunolabeling of cultures was done essentially as described previously
(Turksen and Aubin, 1991; Turksen et al., 1992). Cultures were rinsed
with PBS, fixed with 3.7% formaldehyde in PBS, and permeabilized with
methanol at 
 
 
 
20
 
 
 
C. Frozen sections were fixed 10 min in cold acetone.
Paraffine sections were treated deparaffined in xylene, then rehydrated in
100, 95, and 70% ethanol and water. After rinsing, cells in dishes or frozen
paraffine sections were incubated for 1 h at room temperature with 10%
normal serum in PBS for ERR
 
 
 
 and in 3% BSA in PBS (denaturated) for
OCN, ALP, OPN, and BSP. After rinsing, cells or sections were incubated
for 3 h with appropriate dilutions of purified rabbit polyclonal antibody
described previously (1/50, anti-ERR
 
 
 
). The anti–rat OCN antiserum was
provided by D. Modrowski (INSERM U349, Hospital Lariboisiere, Paris,
France) and used at 1/100 dilution. The anti-OPN (MPIIIB10) and anti-
BSP (WWVIDI) antibodies were purchased from the Hybridoma Bank
and used at a 1/300 and 1/100 dilution, respectively. The production and
characterization of monoclonal antibody RBM 211.13 directed to rat
bone/liver/kidney ALP have been described elsewhere (Turksen and
Aubin, 1991; Turksen et al., 1992); it was used at a 1/100 dilution of puri-
fied ascites fluid. 10% normal serum in PBS or 3% BSA in PBS were used
as negative controls. Nodules or calvaria sections were rinsed in PBS and
incubated for 1 h at room temperature with secondary antibody CY-
3–conjugated anti–rabbit (1/300 final dilution; Jackson ImmunoResearch
Laboratories) for ERR
 
 
 
, OC, and ALP or secondary antibody anti–
mouse (1/300 final dilution; Jackson ImmunoResearch Laboratories) for
BSP and OPN. After rinsing, samples were mounted in Moviol (Hoechst
Ltd.) and observed by epifluorescence microscopy on a ZEISS Photomi-
croscope III (ZEISS). For photography and printing, equal exposure
times were used for specifically labeled and control cultures.
 
Nodule Quantification
 
For quantification of nodule formation, dishes or wells were fixed and
stained by the Von Kossa technique and bone nodules were counted on a
grid (Bellows et al., 1986; Bellows and Aubin, 1989). Results are plotted as
the mean number of nodules 
 
  
 
SD of three wells for controls and each
 
concentration of antisense or sense primers of three independant experi-
ments and five dishes for pcDNA3 control and pcDNA3-ERR
 
 
 
 of five in-
dependent experiments.
 
Cell Counting
 
For cell growth analysis, the cell layers were rinsed in PBS, released with
trypsin and collagenase (1:1, vol/vol, of solutions described above), and the
harvested cells were counted electronically. Results are plotted as the aver-
age of three counts for each of three dishes for control and pcDNA3-ERR
 
 
 
or three wells for each concentration of antisense or sense primers used.
 
ALP Histochemistry
 
The histochemical stain for ALP is a modification of Pearse’s (1960). Cells
were rinsed once with cold PBS and fixed in 10% cold neutral buffered
formalin for 15 min, rinsed with distilled water, and left in distilled water
for 15 min. Fresh substrate (10 mg Naphthol AS MX-PO4 [Sigma-
Aldrich] dissolved in 400 
 
 
 
l N,N-dimethylformamide, then added to 50 ml
distilled water and 50 ml Tris-HCl [0.2 M, pH 8.3] and then 60 mg Red Vi-
olet LB salt [Sigma-Aldrich]), was filtered through Whatman’s No. 1 filter
directly onto the dishes, and incubated for 45 min at 20
 
 
 
C. The dishes were
then rinsed in tap water, drained and stained with 2.5% silver nitrate for
30 min at room temperature (von Kossa stain), then rinsed three times
with tap water. The dishes were finally air dried.
 
Transient Transfections
 
Primary RC cells were grown in 35-mm tissue culture dishes at 2 
 
  
 
10
 
4
 
/
dish in 
 
 
 
-MEM containing 10% heat-inactivated FBS (Flow Laboratories)
and supplemented with 50 
 
 
 
g/ml ascorbic acid, 10 mM sodium 
 
 
 
-glycero-
phosphate, and 10
 
 
 
8
 
 M dexamethasone. Cells were transfected at 50% of
confluence according to the Effectene transfection protocol (QIAGEN)
using a pcDNA3 empty plasmid as a control and pcDNA3-ERR
 
 
 
 (mouse
cDNA full-length from 1–2,211 bp; in the EcoRI cloning site) at 0.5 
 
 
 
g of
total DNA per transfection. As control of transfection efficiency, we used
a CMV-
 
 
 
Gal vector. Nodules were counted at day 15. mRNA was ex-
tracted at 72 h, day 10 (beginning of nodules formation), and day 13
(formed nodules) after transfection.
 
Antisense and Sense Oligonucleotide Treatment
 
The resuspended RC cells were plated in 24-well plates at 10
 
4
 
 cells/well.
Antisense oligonucleotide inhibition of ERR
 
 
 
 expression was accom-
plished with a 20-base phosphorothioate-modified oligonucleotide, local-
ized to the A/B domain, close to the start methionine. This domain is
known not to be highly conserved among members of the nuclear receptor
family. The ERR  antisense oligonucleotide sequence was: 5 -TCAC-
CGGGGGTTCAGTCTCA-3 . This sequence was rigorously analyzed by
Blast search and no homologies were found; this included no homology
with either  R  or ER , ERR  or ERR , or any other currently known
nuclear receptors. The corresponding sense and a scrambled oligonucle-
otide (5 -TCGGCTCACACGGGTTAGCT-3 ) were used as negative
controls. Other control dishes were treated with no oligonucleotide. Pre-
liminary experiments were done to determine effective oligonucleotide
concentrations that were not toxic. 0.1 to 5  M oligonucleotides were
added directly to cells either during the proliferation phase (days 1 to 6)
and 0.5 to 2  M oligonucleotides were added during the differentiation
phase (day 5 [end of proliferation] to 11) in standard medium as above
supplemented with 50  g/ml ascorbic acid, 10 mM sodium  -glycerophos-
phate, and 10 8 M dexamethasone. Medium was changed every 2 d and
fresh oligonucleotides were added. mRNA was collected at day 6 for the
proliferation experiments and at day 15 for the differentiation experi-
ments. Nodules were counted at 15 d.
Statistical Analysis
Results for PCR analysis, bone nodule number (antisense/sense experi-
ments), and cell proliferation were expressed as mean   SD, and analyzed
statistically by one-way analysis of variance (ANOVA) with treatment
group as variance and Bonferroni and Tukey post tests with InStat soft-
ware (v2.01; GraphPad Software). Results for bone nodule number (over-
expression experiment) were expressed as mean   SD and analyzed sta-
tistically by the Mann-Whitney test and Welch test (InStat). Statistical
significance was taken as P   0.05.The Journal of Cell Biology, Volume 153, 2001 974
Results
ERR  mRNA Is Expressed at All Developmental 
Stages of Osteoblast Differentiation and 
Maturation in RC Cells In Vitro
ERR  mRNA expression levels assessed over a prolifera-
tion-differentiation time course by Northern blotting of
primary RC cell populations indicated that ERR  mRNA
was expressed at all times analyzed, including proliferation
(day 6), early nodule formation (day 10), and nodule min-
eralization (day 15) (not shown). However, because RC
cell cultures comprise a heterogeneous mixture of cell
types and osteoblasts at different differentiation stages, we
sought to confirm that ERR  is expressed by osteoblast
lineage cells and clarify its expression pattern over the
proliferation-differentiation sequence of the osteoprogen-
itors. To do this, we used globally amplified (poly[A]
PCR) cDNA pools prepared previously from single iso-
lated osteoblast colonies at different stages of differen-
tiation (Liu et al., 1994; Candeliere et al., 1999; Liu
and Aubin, 1996). Colonies used were selected based on
their molecular phenotypes (relative expression levels of
COLLI, OPN, BSP, ALP, and OCN). ERR  was ampli-
fied in each cDNA pool with specific primers for se-
quences in the 3 UTR of ERR  and normalized to the rel-
ative amounts of total cDNA. ERR  mRNA was found to
be expressed at all developmental times assessed including
in colonies containing primitive progenitors, expressing
only OPN (Fig. 1 A), in progressively more mature colo-
nies expressing COLLI and OPN (Fig. 1 B) or COLLI,
ALP, and OPN (Fig. 1 C), in multilayered colonies con-
taining identifiable cuboidal osteoblasts also expressing
OCN (Fig. 1 D) and, finally, in mineralized bone nodules
(Fig. 1 E).
ERR  Protein Is Expressed in Osteoblastic RC 
Cells In Vitro and in Fetal RC In Vivo
To determine whether ERR  protein is expressed in RC cell
cultures, we performed immunocytochemistry. First, how-
ever, a Western blot of HeLa cell extracts was used to con-
firm the specificity of the ERR  antibody. As expected
based on previously published data (Johnston et al., 1997;
Shigeta et al., 1997), we detected a single immunoreactive
band at 53 kD in Hela (Fig. 2 A) and RC cell extracts (Fig. 3).
As predicted based on the relatively wide tissue distri-
bution of ERR  mRNA in developing mouse embryos
(Bonnelye et al., 1997b) and our results summarized
above, ERR  protein was found to be widely distributed
in most, if not all, cells in RC cultures at all times analyzed,
including early proliferation stages, confluence (data not
shown), when nascent bone nodules were forming (Fig. 2
B, a), and when nodules were mineralizing (Fig. 2 B, b).
However, staining for ERR  was more intense in cuboidal
osteoblasts associated with both early and late bone nod-
ules than in the surrounding fibroblastic cells (Fig. 2 B, a
and b). For comparison, protein expression of two well-
established osteoblast markers, OCN (Fig. 2 B, d) and
OPN (Fig. 2 B, e), both of which are coexpressed at high
levels in the same cuboidal osteoblastic cells expressing
ERR , is also shown. As expected, ERR  was also highly
expressed in cells expressing ALP and BSP (data not
shown).
To extend the observations made in vitro to bones in
vivo, we also performed immunocytochemistry on sections
Figure 1. Detection of ERR  by RT-PCR in
cDNA pools prepared from individual isolated
colonies at different stages of osteoblast differ-
entiation and characterized on the basis of mo-
lecular phenotype and expression of several
known osteoblast lineage markers (OPN and
OCN are shown; other osteoblast markers are
not). The 19 cDNA pools shown represent sev-
eral transitional stages: primitive progenitors
(A), progressively more mature precursors (B,
C, and D), and terminally differentiated, bone-
forming osteoblasts (E). Although category or-
der is progressive, the order of colonies within
each category is random. ERR  mRNA was
normalized with the relative amounts of total
cDNA and detected at all developmental stages,
with a trend to lower expression in the earliest
precursors and most mature osteoblasts in min-
eralized nodules.Bonnelye et al. ERR  and Bone 975
of 21-d fetal RC, the same bones used for preparation of
cell cultures. Consistent with the in vitro results, ERR 
was found in all detectable cohorts of osteoblasts from
those associated with nascent bone at the osteogenic front
(Fig. 2 B, f) to those in the more mature growing bone tra-
becula (Fig. 2 B, g) and remodeling bone (Fig. 2 B, h). Pre-
incubation of the ERR  antibody with the peptide used as
immunogen abolished all specific labeling (Fig. 2 B, i).
Figure 2. ERR  protein with apparent molecular mass of 53 kD is clearly detectable in whole-cell extracts obtained from Hela cells
(A). After SDS-PAGE (10% polyacrylamide), gels were blotted onto nitrocellulose, probed with purified rabbit polyclonal antibody di-
rected against the A/B domain of ERR , and detected with chemiluminescence. ERR  is detectable in vitro by immunolabeling of RC
cells in early differentiation-nascent nodule formation stages (B, a) and later during matrix mineralization (B, b). Immunolabeling of
cuboidal osteoblasts for OCN (B, d) and OPN (B, e) is shown for comparison. The negative secondary antibody control (incubation
without rabbit anti-ERR  antibody) (C ) is shown in (B, c). Bar, 200  m (a–j). ERR  is also detectable in vivo in sections showing dif-
ferent regions of the 21-d fetal RC; at the osteogenic front (B, f), more mature growing bone trabecula (B, g), and remodeling bone (B,
h). Preincubation of the ERR  antibody with the peptide used as immunogen abolishes ERR  labeling (B, i). The negative secondary
antibody control (incubation without rabbit anti-ERR  antibody) is also shown (B, j).The Journal of Cell Biology, Volume 153, 2001 976
Consistent with our reverse transcription (RT)-PCR re-
sults on single bone nodules (see for example Fig. 1),
ERR  was also detectable in sutural cells (arrows, Fig. 2
B, f), preosteoblasts, and osteocytes (Fig. 2 B, g and h).
ERR  was also high in osteocytes present in postnatal (4
wk) RC (data not shown), suggesting that ERR  may be
involved not only in the formation but also in the mainte-
nance of bone.
Inhibition of ERR  Expression Blocks the Proliferation 
of RC Cells and Their Differentiation to Mature
Bone-forming Osteoblasts
Given its expression in both proliferating osteoprogenitor
cells and more mature osteoblasts and osteocytes, we next
asked whether ERR  is a critical factor in osteoblast prolif-
eration and/or differentiation. Antisense oligonucleotides
form DNA–RNA duplexes with specific mRNA species,
thereby blocking binding of the mRNA to the 40S riboso-
mal subunit and preventing translation (Reddy et al.,
1994). As outlined in Materials and Methods, we designed
antisense oligonucleotides to maximize specificity for
ERR  and, by Blast searching, found no evidence for ho-
mology with either ERs or any other nuclear receptors;
controls comprised both a scrambled and a sense oligonu-
cleotide. Preliminary experiments were done to determine
effective oligonucleotide concentrations that were not toxic
(not shown) and the specificity of the antisense was con-
firmed by Western blot on RC cell extracts. After 24 h of
treatment or not with sense or antisense oligonucleotides
on RC cells at day 12, ERR  is detectable as expected in
extracts of untreated cultures and those treated with 2  M
sense oligonucleotides (Fig. 3 B) but is almost undetectable
in cultures treated with 2  M antisense after quantification
with actin used as control (Fig. 3 B). The specificity of the
antisense was also confirmed by immunocytochemistry for
ERR  on bone nodules (data not shown).
To dissect the possible involvement of ERR  in osteo-
blast differentiation and bone formation, we treated RC
cells at different developmental times from early prolifera-
tion stages until mineralized nodule formation (summary,
Fig. 3 A). Treatment of RC cells between days 1–6, the
proliferation stage, caused a significant and specific dose-
dependent decrease, i.e., 13% at 0.5  M, 30% at 1  M, and
40% at 2  M, in cell number at day 6 in dishes treated with
antisense compared with sense, scrambled, or untreated
controls (Fig. 4 A). These results suggest that ERR  may
play a role in the proliferation or very early differentiation
phases of RC cells. To analyze the underlying mechanism
of ERR  action during the proliferation phase, we as-
sessed expression of early markers of osteoblast differenti-
ation (ALP, BSP, OPN, Cbfa1, COLLI), proliferation (cy-
clin D1, c-Fos [data not shown]), and apoptosis (Bcl2,
Bax) at day 6 (Fig. 4 B). BSP and Cbfa1 were reduced sig-
nificantly by 35% (Fig. 4, B and C); cyclin D1 was also re-
duced. On the other hand, ALP, OPN, COLLI, c-Fos,
Bax, and Bcl2 were not affected (Fig. 4, B and C, and data
not shown). To determine whether treatment during the
proliferation time window caused a sustained alteration in
differentiation, we assessed terminal differentiation/bone
nodule formation at day 15 in cultures treated between
days 1–6 with antisense and then switched to normal dif-
ferentiation medium. A significant decrease in mineralized
bone nodule number, i.e., 29% at 1  M and 45% at 2  M
antisense oligonucleotides compared with sense or un-
treated controls (Fig. 5 A), was seen. Concomitantly, we
found that ALP and BSP expression were lower than lev-
els seen in control or sense-treated cultures, whereas
OPN, OCN, and COLLI were not significantly altered
(Fig. 5, B and C).
To determine whether ERR  also plays a role in osteo-
blast differentiation independently of an effect on prolifer-
ation, we next treated RC cells with the antisense or con-
trol oligonucleotides from day 5 (after cells had reached
confluence and proliferation was decreased) to day 11. Al-
though cell number was decreased by day 15 (19% at 1
 M and 35% at 2  M; data not shown) in antisense-
treated cultures, a much larger dose-dependent decrease
in mineralized bone nodule formation was seen, i.e., 30%
at 0.5  M, 60% at 1  M, and 100% decrease at 2  M (Fig.
6, A–C); the sense and scrambled oligonucleotides had a
nonspecific non–dose-dependent effect on nodule num-
bers (Fig. 6, A–C). A similar inhibition of bone nodule for-
mation was also observed when we treated the osteoblas-
tic cell line MC3T3-E1 with the antisense oligonucleotides
Figure 3. Inhibition of ERR  expression
was accomplished with a 20-base phospho-
rothioate-modified antisense (AS) oligonu-
cleotide, localized to the A/B domain of
ERR  (see Materials and Methods for se-
quence). RC cells were treated at different
developmental times from early proliferation
stages through differentiation and mineraliza-
tion as indicated in the summary (A). Control
RC cells were treated either with the comple-
mentary sense (S) oligonucleotide or no oli-
gonucleotide (Ct). The specificity and efficacy
of the antisense treatment are evident from
the Western blot, i.e., decreased intensity of
label for ERR  protein after treatment with 2
 M of antisense (AS, B), but not 2  M sense
(S, B) or no oligonucleotide (Ct, B).Bonnelye et al. ERR  and Bone 977
over a comparable time period (data not shown). In an-
tisense-treated cultures, ALP-positive colonies were pres-
ent and large in diameter but flat, suggesting that inhi-
bition of ERR  blocked differentiation at an early stage
such that progression to matrix deposition and maturation
(Fig. 6 B) was reduced. Consistent with this interpretation,
Cbfa1, BSP, and OCN were all decreased in antisense-
treated cultures whereas OPN, COLLI, and ALP were not
affected (Fig. 7, A and B). Immunocytochemistry con-
firmed the decrease in OCN- and BSP-expressing cells,
but the maintenance of ALP expression in incipient bone
nodules (Fig. 7 C).
Overexpression of ERR  Increases Differentiation 
and Bone Nodule Formation in RC Cells
To address further the putative functional role of ERR  in
osteoblast differentiation suggested by the antisense oligo-
nucleotide treatment, we next asked whether osteoblast
differentiation and bone formation were altered when
ERR  is overexpressed in RC cells. ERR  overexpression
was achieved by transient transfection of day 5 (50–60%
confluent) cultures of RC cells with a CMV-ERR  con-
struct. By using a CMV- Gal control vector, we estimated
that we reproducibly obtained a maximal efficiency of
transfection of 10–15%, which resulted in a 30% increase
in ERR  levels observed on Northern blots (Fig. 8 A).
Consistent with the relatively low transfection efficiency, a
small but statistically significant increase (15%) in the
number of mineralized bone nodules formed by day 15
was observed (Fig. 8 B). In parallel, we assessed expres-
sion levels of osteoblast markers (ALP, OPN, OCN) 72 h
after transfection, at day 10 when bone nodules were be-
ginning to form and at day 13 when nodules were well de-
veloped. We observed an increase in ALP and OPN at
72 h (Fig. 8 C) and day 10 (data not shown) in cultures
overexpressing ERR , consistent with previous data de-
scribing OPN as a target gene of ERR  in reporter assays
(Bonnelye et al., 1997a; Vanacker et al., 1998b). OCN, a
mature osteoblast marker expressed only at later differen-
Figure 4. RC cells were treated
with antisense (AS) or scrambled
(Sc) or sense (S) oligonucleotides at
0.5, 1, and 2  M or no (Ct) oligonu-
cleotide during the proliferation
stage (days 1–6). Inhibition of
ERR  protein synthesis decreased
cell proliferation as evident from
decreased cell number at day 6
(ANOVA, P   0.0001; Bonferroni
and Tukey post tests **P    0.01,
***P   0.001 AS vs. S or Sc). Data
are expressed as the cell number
mean   SD of triplicate wells and
are representative of three inde-
pendent experiment (A). Total
RNA was extracted from parallel
wells and RT-PCR was performed
on triplicate samples by using prim-
ers specific for early markers of os-
teoblast differentiation (ALP, BSP,
OPN, cbfa1, COLLI), proliferation
(cyclin D1), and apoptosis (Bcl2,
Bax) at day 6 (B). The amount of
PCR product for each marker was
normalized to ribosomal protein
L32 PCR product (C). Cbfa1 and
BSP were significantly reduced in
AS-treated cultures (ANOVA; P  
0.05 and P    0.001, respectively;
Bonferroni and Tukey post tests
**P   0.01, ***P   0.001 AS vs. S).The Journal of Cell Biology, Volume 153, 2001 978
tiation times (Fig. 1; see also Liu et al., 1994; Ducy et al.,
1996), was undetectable at 72 h, but was increased at both
day 10 (not shown) and 13 (Fig. 8 C).
Discussion
Our findings show that ERR  is expressed in fetal and
adult RC in vivo and in RC cell cultures in vitro through-
out all osteoblast differentiation stages, from early os-
teoprogenitors to mature osteoblasts. Inhibition of ERR 
expression during the proliferation phase of RC cell cul-
tures with phosphorothioate-modified antisense oligonu-
cleotides decreased proliferation, as seen by a decrease in
cell number and proliferation markers, and reduced differ-
entiation, as seen by a decrease in both mineralized bone
nodule formation and expression levels of osteoblast-asso-
ciated markers. Inhibition of ERR  early during the dif-
ferentiation phase also markedly decreased differentiation
and bone nodule formation. Overexpression of ERR  by
transient transfection in differentiating RC cell cultures
caused a small (15%) but significant increase in mineral-
ized bone nodule formation and markers of osteoblast dif-
ferentiation, consistent with the  10–15% transfection ef-
ficiency and increased ERR  mRNA expression seen in
the primary cell cultures. Although the antisense experi-
ments are not sufficient to formally link functionality of
the receptor with biological activity during osteoblast pro-
liferation and differentiation, taken together with the re-
sults of ERR  overexpression, the data suggest that
ERR  may play a role in bone formation and turnover,
with specific effects on proliferation, progression of differ-
entiation, and mineralization activity of osteoprogenitors
and more mature osteoblasts.
ERR  Is Expressed in Osteoblast Lineage Cells 
throughout Their Developmental Lifetime
We have found that ERR  is expressed at all detectable
stages of osteoblast development, suggesting that ERR 
may have a function in osteoblasts throughout their devel-
Figure 5. RC cells were treated with anti-
sense (AS) or sense (S) oligonucleotides at
0.5, 1, and 2  M or no (Ct) oligonucleotide
during the proliferation stage (days 1–6)
and then switched to normal differentia-
tion medium, to determine if treatment
during the proliferation time window
caused a sustained alteration in differenti-
ation; cultures were fixed at day 15. Inhi-
bition of ERR  protein synthesis resulted
in a decrease in the number of bone nod-
ules (ANOVA; P   0.001; Bonferroni and
Tukey post tests, *P    0.05 AS vs. S).
Data are expressed as the mean number
of nodules   SD of triplicate wells and are
representative of two independent experi-
ments; mineralized nodules were identi-
fied by von Kossa staining at day 15 (A).
Total RNA was extracted from parallel
wells at day 15 and RT-PCR performed
on triplicate samples by using primers spe-
cific for osteoblast markers (ALP, BSP,
OPN, OCN, COLLI) (B). Osteoblast
marker PCR products were normalized to
L32 PCR product (C). ALP and BSP were
reduced significantly (ANOVA, P   0.001)
in both cases; Bonferroni and Tukey post
tests *P   0.05, **P   0.01 AS vs. S.Bonnelye et al. ERR  and Bone 979
opmental lifetime (see also below). In addition to its ex-
pression in fetal calvaria, ERR  is also highly expressed in
adult calvaria (and other fetal and adult bones, data not
shown) and is expressed throughout osteogenesis in adult
rat bone marrow stromal cell cultures (Bonnelye and
Aubin, in preparation), suggesting that it may function
throughout the lifetime of the organism and may be re-
quired not only for bone formation but also for mainte-
nance. In adult quiescent bone, labeling appears highest in
osteocytes, which are thought to be mechanosensors that
send strain-related signals to lining cells located at the bone
surface through the canicular syncytium (Huiskes et al.,
2000), leading to recruitment of osteoblasts among other ef-
fects. The ability of ERR  to transactivate the OPN pro-
moter in osteoblasts suggests a possible mechanism by
which ERR  may contribute to mechanical stress re-
sponses. OPN is expressed in osteocytes and has been
postulated previously to play a bone role in response to
mechanical stress; for example, the enhancement of osteo-
clastic bone resorption and suppression of osteoblastic
bone formation in response to reduced mechanical stress do
not occur in the absence of OPN (Ishijima et al., 2001). The
high levels of expression of ERR  in osteocytes suggest
that it may regulate OPN in this cell type and that disregu-
lation of ERR  expression may alter OPN expression and
concomitantly modify the response to mechanical stress.
ERR  and Proliferation
Consistent with its expression in proliferating osteoblastic
populations, we found that antisense oligonucleotide-
induced downregulation of ERR  inhibits proliferation of
RC cell populations, an inhibition that appears to have
consequences on bone nodule formation at later times (see
below). The decrease in proliferation of RC cells was
somewhat unexpected, given our previous observation that
ERR  expression appears to correlate with exit from pro-
liferation and the onset of the differentiation process in at
Figure 6.  RC cells were treated with antisense (AS), scrambled
(Sc), or sense (S) oligonucleotides at 0.5, 1, and 2  M or no (Ct)
oligonucleotide from day 5 (after cells had reached confluence
and proliferation was decreased) to day 11 (nodules forming);
cultures were fixed on day 15. Inhibition of ERR  protein syn-
thesis resulted in a decrease in the number of bone nodules
(ANOVA; P   0.0001; Bonferroni and Tukey post tests, *P  
0.05 AS vs. S or Sc). Data are expressed as the mean number of
nodules   SD of triplicate wells (C) and are representative of
three independent experiments; mineralized nodules were identi-
fied by combined ALP-von Kossa staining at day 15 (A and B).
(B) Original magnifications:  10 (a and b) and  30 (c and d).
Bar, 1 mm (a–d).The Journal of Cell Biology, Volume 153, 2001 980
least certain other cell types, including the nervous system,
the epidermis, and muscles in the developing mouse
(Bonnelye et al., 1997b). This suggests that ERR  may
play cell type–specific functions and is in keeping with its
detection from the onset of osteogenesis in vivo (Bonnelye
et al., 1997a) and its presence in all osteoblastic cells includ-
ing the earliest detectable osteoprogenitors (current data).
The molecular basis for the ERR  effect on prolifera-
tion is of interest. As OPN has been described as a target
gene of ERR  in vitro promoter-reporter assays (Bon-
nelye et al., 1997a; Vanacker et al., 1998a), and as OPN is
highly expressed in many proliferative populations includ-
ing osteoprogenitors (Fig. 1) and in many tumor cell lines
(for a review, see Denhardt and Noda, 1998), it is one can-
didate target in the proliferation time window for anti-
sense-induced downregulation. However, we found no de-
tectable downregulation of this molecule by antisense
oligonucleotide treatment during this developmental time
window, although it is clearly sensitive to regulation by
ERR  later during the differentiation phase (see below).
The mechanisms underlying this apparently differentia-
tion stage-specific regulation of OPN and perhaps other
target genes of ERR  is not yet clear; however, differenti-
ation stage-specific expression of other coactivators or re-
pressors including ERR  binding partners is one interest-
ing hypothesis. We also found no significant changes in the
antisense-treated RC populations in expression levels of a
variety of proliferation and apoptosis/survival-associated
genes expressed in osteoblasts including c-fos, Bcl-2, and
Bax, although we cannot exclude possible changes in activ-
ity. However, we did observe a significant decrease in cy-
clin D1, a regulator of G1 phase progression. Interestingly,
estrogen induces cell proliferation by stimulating progres-
sion through the G1 phase of the cell cycle (Wakeling et
al., 1991; Clarke et al., 1992), and induction of cyclin D1
expression is a critical feature of the mitogenic response to
Figure 7. Total RNA was ex-
tracted from parallel wells at day 15
and RT-PCR performed on tripli-
cate samples by using primers spe-
cific for osteoblast markers (ALP,
BSP, OPN, OCN, COLLI, Cbfa1)
(A). Osteoblast marker PCR prod-
ucts were normalized to L32 PCR
product. Cbfa1, OCN, and BSP
were reduced by antisense (AS)
treatment (ANOVA; P   0.05, P  
0.001, P   0.001, respectively; Bon-
ferroni and Tukey post tests *P  
0.05, **P   0.01, ***P   0.001 AS
vs. S) (B). Immunocytochemistry
confirmed the decrease in OCN-
and BSP-expressing cells but the
maintenance of ALP expression in
developing bone nodules after
treatment with 2  M sense/anti-
sense (C). Bar, 200  m.Bonnelye et al. ERR  and Bone 981
estrogen. Recently, Sabbah et al. have described a region
in the cyclin D1 promoter that confers regulation by estro-
gens in the human mammary carcinoma cells MCF7 (Sab-
bah et al., 1999). ERR  has been described as a modulator
of the ER–mediated response of the human lactoferrin
gene promoter (Yang et al., 1996), a mechanism that may
also underlie its ability to regulate cyclin D1.
ERR , Osteoblast Differentiation, 
and Matrix Mineralization
Our findings suggest a critical role for ERR  in bone for-
mation, with both up- and downregulation of bone nodule
formation concomitant with up- and downregulation of
ERR  expression in vitro. Even in a background of high
endogenous ERR  expression, further upregulation of
ERR  by transfection of RC cells with a full-length ERR 
expression vector late in the proliferation time window in-
creased bone nodule formation by an amount approxi-
mately equivalent to the transfection efficiency of the
population. Concomitantly, bone markers were also up-
regulated. Whether the increase in osteoprogenitor differ-
entiation and bone nodule formation is a consequence of
upregulation of any of these bone markers, or results from
regulation of another currently unknown ERR  target
gene, remains to be explicitly tested. Further insight into
mechanisms may also be gained from experiments in
which forced expression of ERR  is carried out with sys-
tematic time course and dose response studies.
Downregulation of ERR  either during proliferation
phase or earlier or later in the differentiation sequence
also had marked inhibitory effects on differentiation
and bone nodule formation. Although one can speculate
that the decrease seen when cells are treated only tran-
siently during the proliferation phase reflects the down-
regulation of cyclin D1 and decreased proliferation of
osteoprogenitors among other cells, the decrease could
also reflect the concomitant downregulation of the bone
“master” gene Cbfa1 (Ducy et al., 1997; Komori et al.,
1997) and/or BSP, both of which are upregulated early
during osteoprogenitor cell differentiation (Aubin and
Liu, 1996; Malaval et al., 1999); we also found that BSP
and ERR  are coexpressed in very early osteoprogeni-
tors (Liu et al., 1994). The latter possibility is consistent
with the finding that downregulation of ERR  after
proliferation has largely ceased (antisense treatment
from day 5–11) results in complete inhibition of mineral-
ized bone nodule formation and concomitant downregu-
lation of Cbfa1, BSP, and OCN. These observations, to-
gether with the data on increased bone formation when
ERR  is upregulated early, suggest that at least part of
the effect of ERR  on osteoblast differentiation and
bone formation occurs early during the differentiation
sequence, such that differentiation may not progress be-
yond a certain point when ERR  levels are low. In
keeping with this hypothesis, large flat but ALP-positive
colonies are present in antisense-treated cultures, and a
Figure 8. Primary RC cells at  50% confluency were transfected with either a pcDNA3 empty
plasmid (CMV-empty) or pcDNA3-ERR  (CMV-ERR ) (0.5  g DNA per transfection). Suc-
cessful overexpression of ERR  after transfection was judged by extracting total RNA (pools
from three 35-mm dishes for each condition) 72 h after transfection and Northern blotting (A).
Five 35-mm dishes per treatment group from each of three independent experiments were fixed,
stained by von Kossa, and the nodules were counted (B). ERR  overexpression resulted in a sig-
nificant increase in the number of nodules formed (95% confidence limits shown; Welch test or
Mann Whitney test; P   0.005). Total RNA was extracted from parallel dishes 72 h after transfec-
tion (C) and at day 13 (D), and Northern blots were performed (RNA pooled from three 35-mm
dishes) with probes specific for osteoblast markers (ALP, OPN, OCN).The Journal of Cell Biology, Volume 153, 2001 982
few cells express diminished levels of other osteoblast
markers (Fig. 6).
Manipulation of ERR  levels in this study has served as
a powerful approach to elucidating ERR  function in os-
teoblast development and bone formation in the absence
of a known ligand. ERR  and the ERs share only moder-
ate similarity (36%) in the ligand-binding E domain, which
may explain the fact that ERR  does not bind estrogen.
Although the pesticides chlordane and toxaphene, two or-
ganochlorine compounds with estrogen-like activity, have
been reported to be antagonists of ERR  (Yang and
Chen, 1999), suggesting that ERR  may act as a ligand-depen-
dent repressor, no other ligands/agonists have yet been
reported. On the other hand, the possibility of constitutive
transactivation remains of interest. Constitutive activation
of transcription of the lactoferrin gene by ERR  has been
reported (Zhang and Teng, 2000). The constitutive trans-
activation was seen in cells cultured in phenol red–free
medium supplemented with dextran-charcoal–treated se-
rum, suggesting that ERR  may indeed function as a con-
stitutive transactivator of at least some genes, although the
experiments do not exclude the possibility of an endoge-
nous ligand in particular cell types. Whether osteoblastic
cells may be capable of producing an endogenous ligand
or whether ERR  is functioning as a constitutive transac-
tivator of at least some genes (e.g., BSP, Cbfa1, OCN) in
this cell lineage remains to be determined. In the mean-
time, modulation of levels of this orphan receptor offers
an alternative strategy for functional analysis and identifi-
cation of potential target genes. Such modulation of recep-
tor itself may also contribute to understanding of bone dis-
eases characterized by decreased osteoblast numbers and
reduced bone mass such as osteoporosis and arthritic con-
ditions and to therapeutic strategies to deal with them.
In conclusion, ERR  is expressed in osteoblastic cells in
vitro and in vivo and appears to have a function in prolif-
eration, differentiation, bone nodule formation, and min-
eralization in RC cells. ERR  is expressed in fetal and
adult calvaria and long bone, suggesting that ERR  may
be involved not only in the formation but also in the main-
tenance and turnover of bone throughout the lifetime of
the organism. These results indicate that ERR  may have
an important function in the formation and turnover of the
skeleton but the mechanism by which it does so, i.e.,
through convergence on the ER pathways or by other
mechanisms, remains to be established. They also suggest
that agonists and antagonists of ERR  may be useful as
therapeutic agents in a wide variety of bone metabolic and
other diseases affecting bone.
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